

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 0 967 226 A2**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
29.12.1999 Bulletin 1999/52

(51) Int Cl.⁶: **C07K 14/78**, C12N 15/12,
C12P 21/00

(21) Application number: **99303470.1**

(22) Date of filing: **04.05.1999**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: **08.05.1998 US 84828 P**
10.04.1999 US 289578 P

(71) Applicant: **Cohesion Technologies, Inc.**
Palo Alto, CA 94303 (US)

(72) Inventors:
• **Olsen, David R.**
Menlo Park, CA 94025 (US)
• **Hitzeman, Ronald A.**
Pacifica, CA 94044 (US)
• **Chisholm, George E.**
San Mateo, CA 94403 (US)

(74) Representative: **Goldin, Douglas Michael**
J.A. KEMP & CO.
14 South Square
Gray's Inn
London WC1R 5LX (GB)

(54) **Methods for the production of fibrillar collagen**

(57) Methods are disclosed for simplified recombinant production of fibrillar collagens. DNAs encoding fibrillar collagen monomers lacking the N propeptide,

the C propeptide, or both propeptides are introduced into recombinant host cells and expressed. Trimeric collagen is recovered from the recombinant host cells.

EP 0 967 226 A2

Description

[0001] The invention relates generally to the field of recombinant protein production, and particularly to the production of telopeptide collagen in recombinant host cells.

[0002] Collagen is the major protein component of bone, cartilage, skin and connective tissue in animals. Collagen in its native form is typically a rigid, rod-shaped molecule approximately 300 nm long and 1.5 nm in diameter. It is composed of three collagen polypeptide monomers which form a triple helix. Mature collagen monomers are characterized by a long midsection having the repeating sequence Gly-X-Y, where X and Y are often proline or hydroxyproline, bounded at each end by the "telopeptide" regions, which constitute less than about 5% of the molecule. The telopeptide regions of the chains are typically responsible for the crosslinking between the chains (i.e. the formation of collagen fibrils), and for the immunogenicity of the protein. Collagen occurs naturally in a number of "types" each having different physical properties. The most abundant types in mammals and birds are types I, II, and III.

[0003] Mature collagen is formed by the association of three procollagen monomers which include "pro" domains at the amino and carboxy terminal ends of the polypeptides. The pro domains are cleaved from the assembled procollagen trimer to create mature, or "telopeptide" collagen. The telopeptide domains may be removed by chemical or enzymatic means to create "atelopeptide" collagen.

[0004] Interestingly, although there are a large number of different genes encoding for different procollagen monomers, only particular combinations are produced naturally. For example, skin fibroblasts synthesize 10 different procollagen monomers (pro α 1(I), pro α 1(III), pro α 1(V), pro α 2(I), pro α 2(V), pro α 3(V), pro α 1(VI), pro α 2(VI), pro α 3(VI) and pro α 1(VII)), but only 5 types of mature collagen are produced (types I, III, V, VI and VII).

[0005] Collagen has been utilized extensively in biological research as a substrate for *in vitro* cell culture. It has also been widely used as a component of biocompatible materials for use in prosthetic implants, sustained drug release matrices, artificial skin, and wound dressing and wound healing matrices.

[0006] Historically, collagen has been isolated from natural sources, such as bovine hide, cartilage or bones, and rat tails. Bones are usually dried, defatted, crushed, and demineralized to extract collagen, while cartilage and hide are typically minced and digested with proteolytic enzymes other than collagenase. As collagen is resistant to most proteolytic enzymes (except collagenase), this procedure can conveniently remove most of the contaminating protein that would otherwise be extracted along with the collagen. However, for medical use, species-matched collagen (e.g., human collagen for use in human subjects) is highly desirable in order to minimize the potential for immune response to the collagen material.

[0007] Human collagen may be purified from human sources such as human placenta (see, for example, U.S. Patents Nos. 5,002,071 and 5,428,022). Of course, the source material for human collagen is limited in supply and carries with it the risk of contamination by pathogens such as hepatitis virus and human immunodeficiency virus (HIV). Additionally, the material recovered from placenta is biased as to type and not entirely homogenous.

[0008] Collagen may also be produced by recombinant methods. For example, International Patent Application No. WO 97/14431 discloses methods for recombinant production of procollagen in yeast cells and U.S. Patent No. 5,593,859 discloses the expression of procollagen genes in a variety of cell types. In general, the recombinant production of collagen requires a cloned DNA sequence encoding the appropriate procollagen monomer(s). The procollagen gene(s) is cloned into a vector containing the appropriate DNA sequences and signals for expression of the gene and the construct is introduced into the host cells. Optionally, genes expressing a prolyl-4-hydroxylase alpha subunit and a protein disulfide isomerase are also introduced into the host cells (these are the two subunits which make up prolyl-4-hydroxylase). Addition of the prolyl-4-hydroxylase leads to the conversion of some of the prolyl residues in the procollagen chains to hydroxyproline, which stabilize the triple helix and increase the thermal stability of the protein.

[0009] Alternately, recombinant collagen may be produced using transgenic technology. Constructs containing the desired collagen gene linked to the appropriate promoter/enhancer elements and processing signals are introduced into embryo cells by the formation of ES cell chimera, direct injection into oocytes, or any other appropriate technique. Transgenic production of recombinant collagen is particularly advantageous when the collagen is expressed in milk (i.e., by mammary cells), such as described in U.S. Patent No. 5,667,839 to Berg. However, the production of transgenic animals for commercial production of collagen is a long and expensive process.

[0010] One difficulty of recombinant expression of collagen is the processing of the "pro" regions of procollagen monomers. It is widely accepted that folding of the three monomers to form the trimer begins in the carboxyl pro-region ("C propeptide") and that the C propeptide contains signals responsible for monomer selection (Bachinger et al., 1980, *Eur. J. Biochem.*, **106**:619-632; Bachinger et al., 1981, *J. Biol. Chem.* **256**:13193-13199). One group has identified a region in the carboxy pro-region that they believe is necessary and sufficient for monomer selection (Bulleid et al., 1997, *EMBO J.* **16**(22):6694-6701; Lees et al., 1997, *EMBO J.* **16**(5):908-916; International Patent Application No. WO 97/08311; McLaughling et al., 1998, *Matrix Biol.* **16**:369-377). Additionally, Lee et al. (1992, *J. Biol. Chem.* **267**(33):24126-24133) have shown that deletion of the N propeptide results in decreased secretion of human α 1 pC collagen from CHL cells, but not Mov-13 cells. Accordingly, it is believed that the pro-regions must be retained for proper

chain selection, alignment and folding of collagen produced by recombinant methods. In cells which normally produce collagens, specific proteolytic processing enzymes are produced which remove the N and C propeptides following the secretion of collagen. These enzymes are not present in cells which do not normally produce procollagen (including commonly used recombinant host cells such as bacteria and yeast).

[0011] Ideally, the recombinant production of collagen is accomplished with a recombinant host cell system that has a high capacity and a relatively low cost (such as bacteria or yeast). Because bacteria and yeast do not normally produce the enzyme necessary for processing of the N and C propeptides, the propeptides must be removed after recovering the recombinant procollagen from the host cells. This can be accomplished by the use of pepsin or other proteolytic enzymes such as PRONASE® or trypsin, but *in vitro* processing produces "ragged" ends that do not correspond to the ends of mature collagen secreted by mammalian cells which normally produce fibrillar collagen. Alternately, the enzymes which process the N and C propeptides can be produced and used to remove the propeptides. Any contamination of these enzyme preparations with other proteases will result in ragged ends. This added processing step increases the cost and decreases the convenience of production in these otherwise desirable host cell systems.

[0012] Gelatin can be considered a collagen derivative. Gelatin is denatured collagen, generally in monomeric form, which may be fragmented as well. Gelatin serves a large number of uses, particularly in foodstuffs as well as in medicine, where it is frequently used for coating tablets or for making capsules. However, the possibility of the spread of prion-based diseases through animal-derived gelatin has made the use of animal-derived gelatin less attractive.

[0013] Accordingly, there is a need in the art for simplified methods of producing gelatin and genuine telopeptide collagen in high capacity systems.

[0014] The inventors have discovered new methods for the recombinant production of fibrillar collagens. The inventors have surprisingly and unexpectedly found that co-expression of DNA constructs encoding $\alpha 1(I)$ and $\alpha 2(I)$ collagen monomers lacking the N and C propeptides form heterotrimeric telopeptide collagen having the properties of genuine human type I collagen. Additionally, co-expression in yeast of DNA constructs encoding a non-collagen signal sequence linked to $\alpha 1(I)$ and $\alpha 2(I)$ collagen monomers lacking the N, the C, or both the N and C propeptides results in a surprising increase in the production of type I collagen. Further, the inventors have found that the efficient production of triple helical fibrillar collagen in accordance with the invention is not dependent on hydroxylation of the collagen monomers.

[0015] The methods of the instant invention may be used to produce any of the fibrillar collagens (e.g., types I-III, V and XI), as well as the corresponding types of gelatin, from any species, but are particularly useful for the production of recombinant human collagens for use in medical applications. Collagen produced in accordance with the invention may be hydroxylated (i.e., proline residues altered to hydroxyproline by the action of prolyl-4-hydroxylase) or non-hydroxylated. Additionally, the methods of the invention also provide efficient methods for production of recombinant gelatin.

[0016] In one embodiment, the invention relates to methods for producing fibrillar collagen by culturing a recombinant host cell comprising a DNA encoding a fibrillar collagen monomer lacking a C propeptide sequence selection and alignment domain (SSAD) under conditions appropriate for expression of said DNA; and producing fibrillar collagen. The DNA may encode any of the fibrillar collagen monomers, such as $\alpha 1(I)$, $\alpha 2(I)$, $\alpha 1(II)$, $\alpha 1(III)$, $\alpha 1(V)$, $\alpha 2(V)$, $\alpha 3(V)$, $\alpha 1(XI)$, $\alpha 2(XI)$, and $\alpha 3(XI)$. Optionally, the DNA encoding the fibrillar collagen monomer lacking a C propeptide SSAD may also lack DNA encoding the N propeptide.

[0017] In another embodiment, the invention relates to methods for producing fibrillar collagen by culturing a recombinant yeast host cell comprising a DNA encoding a fibrillar collagen monomer lacking a N propeptide under conditions appropriate for expression of said DNA; and producing fibrillar collagen.

[0018] Another embodiment relates to recombinant host cells comprising an expression construct comprising a DNA encoding a fibrillar collagen monomer lacking a C propeptide sequence selection and alignment domain (SSAD). The DNA may encode any of the fibrillar collagen monomers, such as $\alpha 1(I)$, $\alpha 2(I)$, $\alpha 1(II)$, $\alpha 1(III)$, $\alpha 1(V)$, $\alpha 2(V)$, $\alpha 3(V)$, $\alpha 1(XI)$, $\alpha 2(XI)$, and $\alpha 3(XI)$. Optionally, the DNA encoding the fibrillar collagen monomer lacking a C propeptide SSAD may also lack DNA encoding the N propeptide.

[0019] In a further embodiment, the invention relates to trimeric collagen molecules which lack propeptide domains and lack native glycosylation and trimeric collagen molecules which lack propeptide domains and lack any glycosylation. The trimeric collagens of the invention have "genuine" ends (i.e., the amino and carboxy-terminal residues which would be produced by normal processing in tissues which naturally produce collagen).

[0020] Another embodiment of the invention relates to the production of recombinant gelatin. Gelatin may be produced using constructs encoding any collagen monomer, preferably lacking the C propeptide domain and/or the N propeptide domain in a recombinant host cell. The collagen monomers thus produced may be hydroxylated (e.g., produced in a cell with prolyl-4-hydroxylase activity) or non-hydroxylated. After collection and any purification, the collagen monomers are denatured as necessary to form gelatin, although non-hydroxylated collagen monomers expressed in host cells incubated at elevated temperatures may not require any further treatment to form gelatin.

BRIEF DESCRIPTION OF THE DRAWINGS

[0021] FIG. 1 shows an alignment of SSAD sequences, shown in single letter amino acid code, as identified by Lees et al. (1997, *supra*). Positions 1-12 and 21-23 are considered the essential positions in the SSAD.

[0022] FIG. 2 shows a map of shuttle vector plasmid Gp5432.

[0023] FIG. 3A and FIG. 3B show the amino acid sequence of human prepro α 1(I) collagen posted to Genbank under accession number AF017178. The signal sequence (pre domain) is underlined. The first amino acid of the N telopeptide is marked with an "***". The last amino acid of the C telopeptide is marked with a "#".

[0024] FIG. 4A and FIG. 4B show the amino acid sequence of human prepro α 2(I) collagen posted to Genbank under accession number Z74616. The signal sequence (pre domain) is underlined. The first amino acid of the N telopeptide is marked with an "***". The last amino acid of the C telopeptide is marked with a "#".

[0025] FIG. 5 shows a half-tone reproduction of a western blot demonstrating results from a thermal stability protease assay. Lanes labeled HSF are samples of type I procollagen from medium conditioned by human skin fibroblasts. Lanes labeled CYT29 (strain GY5344 transformed with pD0248053) are collagen produced in yeast using an expression construct encoding preproHSA α 1(I) and preproHSA α 2(I) (preproHSA α 1(I) and preproHSA α 2(I) comprise the human serum albumin signal sequence plus four amino acids of the pro domain linked to a KEX2 cleavage site fused to the α 1(I) and α 2(I) telopeptide collagen monomers).

[0026] FIG. 6 shows a half-tone reproduction of a western blot demonstrating results from a mammalian collagenase digest of human skin fibroblast and yeast-derived collagen. Lanes labeled HSF are samples of type I procollagen from human skin fibroblasts. Lanes labeled CYT29 are collagen produced in yeast using an expression construct encoding preproHSA α 1(I) and preproHSA α 2(I).

[0027] FIG. 7 shows a map of shuttle vector plasmid Gp5102.

[0028] FIG. 8 shows a map of the shuttle vector plasmid pD0248053. The "***" marks the location of the stop sequence TAATGA at the ends of the C telopeptides.

[0029] FIG. 9 shows a bar graph depicting procollagen production in different media formulations.

[0030] FIG. 10 shows a transmission electron micrograph of recombinant collagen fibrils.

[0031] FIG. 11 shows a map of the shuttle vector plasmid Gp5511

[0032] FIG. 12 shows a map of the shuttle vector plasmid Gp5551.

[0033] The methods of the instant invention generally involve the use of recombinant host cells comprising DNA expression constructs encoding the production of fibrillar collagen monomers lacking at least portions of one or both of the propeptides. The recombinant host cells are incubated under conditions appropriate for the expression of the constructs, and trimeric telopeptide collagen is recovered.

Definitions

[0034] As used herein, the term "collagen" refers to a family of homotrimeric and heterotrimeric proteins comprised of collagen monomers. There are a multitude of known collagens (at least 19 types) which serve a variety of functions in the body. There are an even greater number of collagen monomers, each encoded by a separate gene, that are necessary to make the different collagens. The most common collagens are types I, II, and III. Collagen molecules contain large areas of helical structure, wherein the three collagen monomers form a triple helix. The regions of the collagen monomers in the helical areas of the collagen molecule generally have the sequence G-X-Y, where G is glycine and X and Y are any amino acid, although most commonly X and Y are proline and/or hydroxyproline. Hydroxyproline is formed from proline by the action of prolyl-4-hydroxylase, and is believed to contribute to the thermal stability of trimeric fibrillar collagen. The term "collagen", as used herein, may refer to hydroxylated fibrillar collagen (*i.e.*, collagen containing hydroxyproline) or non-hydroxylated fibrillar collagen (*i.e.*, collagen without hydroxyproline).

[0035] As used herein, the term "fibrillar collagen" means a collagen of a type which can normally form collagen fibrils. The fibrillar collagens are collagen types I-III, V, and XI. The collagen monomers that make up the fibrillar collagens contain "telopeptide" regions at the amino (N) and carboxy (C) terminal ends of the monomers which are non-helical in the collagen trimer. These collagens self-assemble into fibrils with the C-terminal end of the helical domain and the C propeptide of one collagen triple helix overlapping with the N telopeptide and the N-terminal end of the triple helical domain of an adjacent collagen molecule. The monomers that make up the fibrillar collagens are made as preproteins, including an N-terminal secretion signal sequence and N and C-terminal propeptide domains. The signal sequence is normally cleaved by signal peptidase, as with most secreted proteins, and the propeptides are removed by specific proteolytic processing enzymes after association, folding and secretion of trimeric procollagen. The term fibrillar collagen encompasses both native (*i.e.*, naturally occurring) and variant fibrillar collagens (*i.e.*, fibrillar collagens with one or more alterations in the sequence of one or more of the fibrillar collagen monomers). Unless the context clearly indicates otherwise (*e.g.*, the term is modified by the word "monomer") "fibrillar collagen" refers to triple helical fibrillar collagen.

[0036] The term "pC" refers to a fibrillar collagen (monomer or triple helical, trimeric molecule) which lacks a collagen N propeptide.

[0037] The term "pN" refers to a fibrillar collagen (monomer or triple helical, trimeric molecule) which lacks a collagen C propeptide.

[0038] The term "gelatin" refers to compositions comprising non-helical collagen monomers or fragments thereof. The collagen monomers may be fibrillar collagen monomers or non-fibrillar collagen monomers. Additionally, the collagen monomers (fibrillar or non-fibrillar) may be hydroxylated or non-hydroxylated.

[0039] A "heterologous prepro sequence" refers to an amino acid sequence derived from a protein other than a collagen which functions as a prepro sequence in its normal setting. A heterologous prepro sequence may include sequences not found in association with the heterologous prepro sequence in its natural setting, such as a protease recognition site sequence. A preferred example of a preferred heterologous prepro sequence is the prepro sequence from human serum albumin, which includes at its carboxy terminal end the amino acid sequence Arg-Arg, which is a KEX2 recognition site.

[0040] The term "sequence selection and alignment domain" or "SSAD" refers to a portion of the C propeptide of fibrillar collagens identified by Lees et al. (1997, *supra*) as responsible for chain selection and alignment. SSAD sequences for $\alpha 1(I)$, $\alpha 2(I)$, $\alpha 1(II)$, $\alpha 1(III)$, $\alpha 1(V)$, $\alpha 2(V)$, $\alpha 1(XI)$, and $\alpha 2(XI)$ have been identified in Lees et al. and are shown in Fig. 1. Only positions 1-12 and 21-23 of the sequences shown in Fig. 1 are considered part of the SSAD. SSADs from other fibrillar collagen monomers can easily be identified in the C propeptide of fibrillar collagen monomers by sequence similarity alignment with the SSADs shown in Fig. 1.

[0041] The term "DNA encoding a fibrillar collagen monomer", as used herein, means a DNA sequence which encodes a collagen monomer that is a component of a fibrillar collagen and which lacks the N propeptide domain, the SSAD, or both. cDNAs encoding fibrillar collagen monomers have been identified, cloned and sequenced, and are readily available to the research community through Genbank and other DNA sequence depositories. Due to the large size of the collagen monomers, the primary source of sequence information is cloned DNA sequence. By conceptual translation, the amino acid sequence of the fibrillar collagen monomers can be deduced. A DNA encoding a fibrillar collagen monomer is any DNA sequence that encodes the amino acid sequence of a fibrillar collagen monomer. Due to the degeneracy of the DNA code, a large number of different DNA sequences will be useful for the expression of any given fibrillar collagen monomer. Additionally, due to codon usage bias, the DNAs useful in the instant invention may be selected to be particularly advantageous for use in particular host cell (e.g., for use in *S. cerevisiae*, DNAs encoding fibrillar collagen monomers may be selected or synthesized which utilize codons that are preferred in *S. cerevisiae*).

[0042] The terms "defined media" or "defined medium", as used herein, means a medium for the culture of recombinant host cells which does not contain cell or tissue extracts (e.g., yeast extract, casamino acids) or serum. A defined medium normally contains vitamins, minerals, trace metals, amino acids, a carbon source, a nitrogen source, and may optionally contain a pH buffering system. If the defined medium is for use with higher eukaryotic cells, then the defined medium may also contain hormones, peptide growth factors and other proteins necessary for cell survival and growth.

[0043] A "semi-defined" medium is a medium which does not contain any unmodified animal or cell derived components. For example, a semi-defined medium may contain casamino acids, but not serum or conditioned medium.

[0044] DNA encoding any collagen monomer that is a component of fibrillar collagen may be useful in the methods of the instant invention. Particularly preferred collagen monomers are $\alpha 1(II)$, $\alpha 2(I)$, $\alpha 1(II)$, $\alpha 1(III)$, $\alpha 1(V)$, $\alpha 2(V)$, $\alpha 3(V)$, $\alpha 1(XI)$, $\alpha 2(XI)$, and $\alpha 3(XI)$, more preferably the human forms of $\alpha 1(I)$, $\alpha 2(I)$, $\alpha 1(II)$, $\alpha 1(III)$, $\alpha 1(V)$, $\alpha 2(V)$, $\alpha 3(V)$, $\alpha 1(XI)$, $\alpha 2(XI)$, and $\alpha 3(XI)$. The amino acid sequences for these proteins are available to the public (see, for example, Tromp et al., 1988, *Biochem J.* **253**(3):919-922; Kuivaniemi et al., 1988, *Biochem J.* **252**(3):633-640; Su et al., 1989, *Nucleic Acid Res.* **17**(22):9473; Ala-Kokko et al., 1989, *Biochem. J.* **260**(2):509-516; Takahara et al., 1991, *J. Biol. Chem.* **266**(20): 13124-13129; Weil et al., 1987, *Nucleic Acid Res.* **15**(1):181-198; Bernard et al., 1988, *J. Biol. Chem.* **263**(32): 17159-17166; Kimura et al., 1989, *J. Biol. Chem.* **264**(23):13910-13916; Mann et al., 1992, *Biol. Chem. Hoppe Seyler* **373**:69-75; Sandell et al., 1991, *J. Cell. Biol.*, **114**:1307-1319). Additionally, deletion mutants of fibrillar collagens such as that described in Sieron et al. (1993, *J. Biol. Chem.* **268**(28):21232-21237) and D period deletions such as described in Zafarullah et al. (1997, *Matrix Biol.* **16**:245-253) and Arnold et al. (1997, *Matrix Biol.* **16**:105-116) may also be produced by the method of the instant invention. The DNAs may be obtained by any method from any source known in the art, such as isolation from cDNA or genomic libraries, chemical synthesis, or amplification from any available template. Additionally, DNAs encoding variants may be produced by *de novo* synthesis or by modification of an existing DNA by any of the methods known in the art.

[0045] DNA encoding fibrillar collagen monomers for use in accordance with the instant invention lack sequences encoding the N propeptide, the C propeptide SSAD, or both. Lees et al. (1997, *supra*) teach that the SSAD domain is required for proper chain selection and association of collagen monomers. Preferably, DNAs encoding fibrillar collagen monomers lack the SSAD and also lack sequence encoding at least 50% of the total C propeptide domain, more preferably at least 75% of the total C propeptide domain, and even more preferably total 90% of the propeptide domain,

and most preferably DNAs encoding fibrillar collagen monomers lack all of the C propeptide domain. Alternately, the DNA encoding fibrillar collagen monomers may lack sequence encoding part or all of the N propeptide domain. Preferred deletions of the sequence encoding the N propeptide domain include DNAs lacking sequence encoding 50%, 75%, 90% or all of the N propeptide. Additionally, DNA encoding fibrillar collagen monomers may lack sequence encoding portions of or the entirety of the N and C propeptides. Preferably, the DNA encoding fibrillar collagens for use in accordance with the instant invention lack sequences encoding both the N and C propeptides. The boundaries of the mature peptide and the N and C propeptides are well known in the art.

[0046] DNA encoding fibrillar collagen monomers and non-fibrillar collagen monomers are useful for the production of gelatin in accordance with the instant invention. DNA encoding human collagen monomer(s) is preferred for the production of gelatin. As for fibrillar collagen monomers, the sequences of non-fibrillar collagens are also well known to those of skill in the art, and may be obtained using conventional techniques such as library screening, polymerase chain reaction amplification, or chemical synthesis. The DNA for use in production of gelatin in accordance with the invention is preferably lacking 50%, 75%, 90% or all of the sequence encoding the N propeptide and/or 50%, 75%, 90% or all of the sequence encoding the C propeptide. Preferably, DNA encoding collagen monomers for use in production of gelatin lacks sequence encoding both the N and C propeptides.

[0047] For use in the instant invention, the DNA encoding a fibrillar collagen monomer or a non-fibrillar collagen monomer is cloned into an expression construct. General techniques for nucleic acid manipulation useful for the practice of the claimed invention are described generally, for example, in Sambrook et al., *MOLECULAR CLONING: A LABORATORY MANUAL*, Vols. 1-3 (Cold Spring Harbor Laboratory Press, 2 ed., (1989); or F. Ausubel et al., *CURRENT PROTOCOLS IN MOLECULAR BIOLOGY* (Green Publishing and Wiley-Interscience: New York, 1987) and periodic updates.

[0048] The exact details of the expression construct will vary according to the particular host cell that is to be used as well as to the desired characteristics of the expression system, as is well known in the art. For example, for production in *S. cerevisiae*, the DNA encoding a fibrillar collagen monomer or non-fibrillar collagen monomer is placed into operable linkage with a promoter that is operable in *S. cerevisiae* and which has the desired characteristics (e.g., inducible/derepressible or constitutive). Where bacterial host cells are utilized, promoters and promoter/operators such as the *araB*, *trp*, *lac*, *gal*, *tac* (a hybrid of the *trp* and *lac* promoter/operator), *T7*, and the like are useful in accordance with the instant invention. Acceptable promoters for use in the instant invention where the host cell is *S. cerevisiae* include, but are not limited to *GAL1-10*, *PHO5*, *PGK1*, *GDP1*, *PMA1*, *MET3*, *CUP1*, *GAP*, *TPI*, *MF α 1* and *MF α 2*, as well as the hybrid promoters *PGK/ α 2*, *TPI/ α 2*, *GAP/GAL*, *PGK/GAL*, *GAP/ADH2*, *GAP/PHO5*, *ADH2/PHO5*, *CYC1/GRE*, and *PGK/ARE*, and other promoters active in *S. cerevisiae* as are known in the art. Where *S. pombe* is utilized as the host cell, promoters such as *FBP1*, *NMT1*, *ADH1* and other promoters active in *S. pombe* as are known in the art, such as the human cytomegalovirus (hCMV) LTR. The AOX1 promoter is preferred when *Pichia pastoris* is the host cell, although other promoters known in the art, such as *GAP* and *PGK* are also acceptable. Further guidance with regard to features of expression constructs for yeast host cells may be found in, for example, Romanos et al. (1992, *Yeast* 8: 423-488). When other eukaryotic cells are the desired host cell, any promoter active in the host cell may be utilized. For example, when the desired host cell is a mammalian cell line, the promoter may be a viral promoter/enhancer (e.g., the herpes virus thymidine kinase (TK) promoter or a simian virus promoter (e.g., the SV40 early or late promoter) or a long terminal repeat (LTR), such as the LTR from cytomegalovirus (CMV), Rous sarcoma virus (RSV) or mouse mammary tumor virus (MMTV)) or a mammalian promoter, preferably an inducible promoter such as the metallothionein or glucocorticoid receptor promoters and the like.

[0049] Expression constructs may also include other DNA sequences appropriate for the intended host cell. For example, expression constructs for use in higher eukaryotic cell lines (e.g., vertebrate and insect cell lines) will include a polyadenylation site and may include an intron (including signals for processing the intron), as the presence of an intron appears to increase mRNA export from the nucleus in many systems. Additionally, a secretion signal sequence operable in the host cell is normally included as part of the construct. The secretion signal sequence may be from a collagen monomer gene or from a non-collagen gene. In one preferred embodiment, the secretion signal sequence is a prepro sequence derived from human serum albumin which contains a KEX2 protease processing site (MKWVTFISLLFLFSSAYS RGVFRR in single letter amino acid code, the signal peptidase site is between S and R, RGVF is derived from the HSA pro domain). If the secretion signal sequence is derived from a collagen monomer gene, it may be from a fibrillar collagen monomer (and may be derived from the same protein as the DNA encoding the fibrillar collagen monomer to be expressed or from a different fibrillar collagen monomer) or a non-fibrillar collagen monomer. Where the expression construct is intended for use in a prokaryotic cell, the expression construct may include a signal sequence which directs transport of the synthesized peptide into the periplasmic space or expression may be directed intracellularly.

[0050] Preferably, the expression construct will also comprise a means for selecting for host cells which contain the expression construct (a "selectable marker"). Selectable markers are well known in the art. For example, the selectable marker may be a resistance gene, such as an antibiotic resistance gene (e.g., the *neo^r* gene which confers resistance

to the antibiotic gentamycin), or it may be a gene which complements an auxotrophy of the host cell. If the host cell is a yeast cell, the selectable marker is preferably a gene which complements an auxotrophy of the cell (for example, complementing genes useful in *S. cerevisiae*, *P. pastoris* and *S. pombe* include *LEU2*, *TRP1*, *TRP1d*, *URA3*, *URA3d*, *HIS3*, *HIS4*, *ARG4*, *LEU2d*), although antibiotic resistance markers such as SH BLE, which confers resistance to ZEOCIN®, may also be used. If the host cell is a prokaryotic or higher eukaryotic cell, the selectable marker is preferably an antibiotic resistance marker (e.g., *neo^r* or *bla*). Alternately, a separate selectable marker gene is not included in the expression vector, and the host cells are screened for the expression product of the DNA encoding the fibrillar collagen monomer (e.g., upon induction or derepression for controllable promoters, or after transfection for a constitutive promoter, fluorescence-activated cell sorting, FACS, may be used to select those cells which express the recombinant collagen). Preferably, the expression construct comprises a separate selectable marker gene.

[0051] The expression construct may also contain sequences which act as an "ARS" (autonomous replicating sequence) which will allow the expression construct to replicate in the host cell without being integrated into the host cell chromosome. Origins of replication for bacterial plasmids are well known. ARS for use in yeast cells are also well known (the 2 μ origin of replication and operative fragments thereof, especially the full length sequence 2 μ is preferred, see, for example International Patent Application No. WO 97/14431, although *CEN*-based plasmids and YACS are also useful in the instant invention) and ARS which act in higher mammalian cells have been recently described (see, for example, Pelletier et al., 1997, *J. Cell. Biochem.* 66(1):87-97). Alternately, the expression construct may include DNA sequences which will direct or allow the integration of the construct into the host cell chromosome by homologous or site-directed recombination.

[0052] Where the host cell is a eukaryotic cell, it may be advantageous for the expression vector to be a "shuttle vector", because manipulation of DNA is substantially more convenient in bacterial cells. A shuttle vector is one which carries the necessary signals to for manipulations in bacteria as well as the desired host cell. So, for example, the expression construct may also comprise an ARS ("ori") which acts in prokaryotic cells as well as a selectable marker which is useful for selection of prokaryotic cells.

[0053] The host cells for use in the instant invention may be any convenient host cell, including bacterial, yeast, and eukaryotic cells. Yeast and higher eukaryotic cells are preferred host cells. For yeast host cells, *Saccharomyces cerevisiae*, *Pichia pastoris*, *Hansenula polymorpha*, *Kluyveromyces lactis*, *Schwanniomyces occidentis*, *Schizosaccharomyces pombe* and *Yarrowia lipolytica* strains are preferred. Of the higher eukaryotic cells, insect cells such as Sf9 are preferred, as are mammalian cell lines which produce non-fibrillar collagens and do not produce any endogenous fibrillar collagens, such as HT-1080, 293, and NSO cells.

[0054] If the host cell does not have prolyl-4-hydroxylase activity (or has insufficient activity as is the case in insect cells), the host cell may be altered to produce prolyl-4-hydroxylase, although this is not necessary for collagen production in yeast *per se*, as the inventors have found that prolyl-4-hydroxylase is not required for the efficient recombinant production of collagen in yeast. However, because hydroxyproline residues contribute to the thermal stability of the collagen triple helix, it may be desirable to produce collagen in a host cell with sufficient prolyl-4-hydroxylase activity. This may be conveniently accomplished by introducing expression constructs coding for the expression of the subunits of prolyl-4-hydroxylase into the host cell. Prolyl-4-hydroxylase is a tetramer comprising two α subunits and two β subunits ($\alpha_2\beta_2$). The β subunit is also known as protein disulfide isomerase (PDI). Expression constructs for prolyl-4-hydroxylase have been described for yeast (Vuorela et al., 1997, *EMBO J* 16(22):6702-6712) and for insect cells (Lamberg et al., 1996, *J. Biol. Chem.* 271(20):11988-11995). In the case of a bacterial host cell, the expression construct for prolyl-4-hydroxylase will preferably incorporate a translocation signal to direct the transport of the subunits of the enzyme to the periplasmic space. Alternately, the prolyl-4-hydroxylase expression construct may be included in the fibrillar collagen monomer construct. In this arrangement, the expression construct may direct the production of separate messages for the fibrillar collagen monomer and the prolyl-4-hydroxylase subunits or it may direct the production of a polycistronic message. Separate messages are preferred for eukaryotic hosts, while the expression of a polycistronic message is preferred for prokaryotic hosts.

[0055] Alternately, the collagen produced in accordance with the invention may be produced in non-hydroxylated form. Non-hydroxylated fibrillar collagen has reduced thermal stability compared to hydroxylated fibrillar collagen. Fibrillar collagen with reduced thermal stability may be desirable for certain uses. However, non-hydroxylated (as well as hydroxylated collagen) may be modified to increase thermal stability by chemical modification such as, for example, chemical crosslinking.

[0056] The expression construct is introduced into the host cells by any convenient method known to the art. For example, for yeast host cells, the construct may be introduced by electroporation, lithium acetate/PEG and other methods known in the art. Higher eukaryotes may be transformed by electroporation, microprojectile bombardment, calcium phosphate transfection, lipofection, or any other method known to the art. Bacterial host cells may be transfected by electroporation, calcium chloride-mediated transfection, or any other method known in the art.

[0057] After introduction of the expression construct into the host cell, host cells comprising the expression construct are normally selected on the basis of the selectable marker that is included in the expression vector. As will be apparent,

the exact details of the selection process will depend on the identity of the selectable marker. If the selectable marker is an antibiotic resistance gene, the transfected host cell population is generally cultured in the presence of an antibiotic to which resistance is conferred by the selectable marker. The antibiotic eliminates those cells which are not resistant (i.e., those cells which do not carry the resistance gene) and allows the propagation of those host cells which carry the resistance gene (and presumably carry the rest of the expression construct as well). If the selectable marker is a gene which complements an auxotrophy of the host cells, then the transfected host cell population is cultured in the absence of the compound for which the host cells are auxotrophic. Those cells which are able to propagate under these conditions carry the complementing gene to supply this compound and thus presumably carry the rest of the expression construct.

[0058] Host cells which pass the selection process may be "cloned" according to any method known in the art that is appropriate for the host cell. For microbial host cells such as yeast and bacteria, the selected cells may be plated on solid media under selection conditions, and single clones may be selected for further selection, characterization or use. Higher eukaryotic cells are generally further cloned by limiting dilution (although physical isolation methods such as micromanipulation or "cloning rings" may also be used). This process may be carried out several times to ensure the stability of the expression construct within the host cell.

[0059] For production of trimeric collagen, the recombinant host cells comprising the expression construct are generally cultured to expand cell numbers. This expansion process may be carried out in any appropriate culturing apparatus known to the art. For yeast and bacterial cells, an apparatus as simple as a shaken culture flask may be used, although large scale culture is generally carried out in a fermenter. For insect cells, the culture is generally carried out in "spinner flasks" (culture vessels comprising a means for stirring the cells suspended in a liquid culture medium). For mammalian cell lines, the cells may be grown in simple culture plates or flasks, but as for the yeast and bacterial host cells, large scale culture is generally performed in a specially adapted apparatus, a variety of which are known in the art.

[0060] The culture medium used for culture of the recombinant host cells will depend on the identity of the host cell. Culture media for the various host cells used for recombinant culture are well known in the art. The culture medium generally comprises inorganic salts and compounds, amino acids, carbohydrates, vitamins and other compounds which are either necessary for the growth of the host cells or which improve the health and/or growth of the host cells (e.g., protein growth factors and hormones where the host cells are mammalian cell lines). Semi-defined media and defined media are preferred for use in the instant invention.

[0061] Where the host cells are yeast cells, the inventors have identified media formulations which utilize no animal-derived components, such as casamino acids, that are advantageous for the production of collagen in accordance with the invention. Preferred media include media with a defined "base" medium (such as YNB) that is supplemented with specific amino acids. Preferred amino acids for supplementation include arginine, glutamate, lysine, and α -ketoglutarate. Where the defined media is supplemented with α -ketoglutarate, the media is preferably buffered to an initial acid pH, preferably about pH 5.5 to 6.5, more preferably about pH 6.0 as the pH of the media at the beginning of the culture.

[0062] If the host cells comprise (either naturally or by introduction of the appropriate expression constructs) prolyl-4-hydroxylase, then vitamin C (ascorbic acid or one of its salts) may be added to the culture medium, although applicants have found ascorbate may not be necessary if the recombinant host cells are *S. cerevisiae* cells. If ascorbic acid is added, it is generally added to a concentration of between 10-200 μ g/ml, preferably about 80 μ g/ml. If ascorbate is to be added, it need not be added until the host cells begin producing recombinant collagen.

[0063] The recombinant host cells are cultured under conditions appropriate for the expression of the DNA encoding the fibrillar collagen monomer. If the expression construct utilizes a controllable expression system, the expression of the DNA encoding the fibrillar collagen monomers is induced or derepressed, as is appropriate for the particular expression construct. The exact method of inducing or derepressing the expression of the DNA encoding the fibrillar collagen monomers will depend on the properties of the particular expression construct used and the identity of the host cell, as will be apparent to one of skill in the art. Generally, for inducible promoters, a molecule which induces expression is added to the culture medium. For example, in yeast transfected with an expression vector utilizing the GAL 1-10 promoter, galactose is added to the culture medium in the absence or presence of dextrose, depending on the yeast strain utilized. In bacteria utilizing an expression vector with the *lac* promoter, isopropyl- β -D-thiogalactopyranoside (IPTG) is added to the medium to derepress expression. For constitutive promoters, the cells are cultured in a medium providing the appropriate environment and sufficient nutrients to support the survival of the cells and the synthesis of the fibrillar collagen monomers.

[0064] It should be noted that for production of trimeric collagen, host cells which do not produce active prolyl-4-hydroxylase should be induced at reduced temperatures (e.g., about 15-25° C, more preferably about 20° C), to avoid thermal denaturation of the unhydroxylated trimeric fibrillar collagen. Production of gelatin in host cells which do not produce active prolyl-4-hydroxylase may be accomplished at higher induction temperatures (e.g., about 26-37° C, preferably about 30° C).

[0065] Mature fibrillar collagen is produced by the recombinant host cells. Surprisingly, the fibrillar collagen monomers assemble into mature collagen trimers in the absence of the C propeptide.

[0066] Fibrillar collagen may then be recovered from the culture. The exact method of recovery of the collagen from the culture will depend on the host cell type and the expression construct. In many microbial host cells, the collagen will be trapped within the cell wall of the recombinant host cell, even though it has been transported out of the cytoplasm. In this instance, the host cells are preferably disrupted to recover the fibrillar collagen. Alternately, cell walls may be removed or weakened to release fibrillar collagen located in the periplasm. Disruption may be accomplished by any means known in the art, including sonication, microfluidization, lysis in a french press or similar apparatus, disruption by vigorous agitation/milling with glass beads, or lysis of osmotically fragile mutant yeast strains (Broker, 1994, *Bio-techniques* 16:604-615) and the like. Where the collagen is recovered by lysis or disruption of the recombinant host cells, the lysis or disruption is preferably carried out in a buffer of sufficient ionic strength to allow the collagen to remain in soluble form (e.g., more than 0.1 M NaCl, and less than 4.0 M total salts including the buffer). Alternately, in higher eukaryotic cells or microbial cells having mutations which render the cell wall "leaky", the fibrillar collagen may be recovered by collection of the culture medium.

[0067] When DNAs encoding collagen monomers lacking the N and C propeptides are utilized in yeast or prokaryotic cells in accordance with the methods of the instant invention, non-glycosylated trimeric collagen having genuine N and C terminal ends (i.e., the N and C telopeptide ends found in fibrillar collagens secreted from mammalian cells that normally produce fibrillar collagen) is produced.

[0068] Recovered collagen may be further purified. As with recovery, the method of purification will depend on the host cell type and the expression construct. Generally, recovered collagen solutions are clarified (if the collagen is recovered by cell disruption or lysis). Clarification is generally accomplished by centrifugation, but may also be accomplished by sedimentation and/or filtration if desired. The collagen-containing solution may also be delipidated when the collagen solution contains substantial amounts of lipids (such as when the collagen is recovered by cellular lysis or disruption). Delipidation may be accomplished by the use of an adsorbant such as diatomaceous earth or diatomite such as that sold as CELITE® 512. When diatomaceous earth or diatomite is utilized for delipidation, it is preferably prewashed before use, then removed from the delipidated solution by filtration.

[0069] Collagen purification may be accomplished by any purification technique(s) known in the art. Collagen solubility can be manipulated by alterations in buffer ionic strength and pH. Collagen can be induced to: precipitate at high ionic strengths; dissolve in acidic solutions; form fibrils (by assembly of trimeric monomers) in low ionic strength buffers near neutral pH (i.e., about pH 6 to 8), thereby eliminating proteins which do not precipitate at high ionic strength; resolubilize in acidic solutions; and become insoluble in low ionic strength buffers, respectively. Any one of these manipulations may be used, singly or in combination with others to purify collagen of the invention. Additionally, solubilized collagen may be purified using any conventional purification techniques known in the art, including gel filtration chromatography, ion exchange chromatography (generally cation exchange chromatography to adsorb the collagen to the matrix, although anion exchange chromatography may also be used to remove a contaminant from the collagen-containing solution), affinity chromatography, hydrophobic interaction chromatography, and high performance liquid chromatography (Miller et al., 1982, *Meth. Enzymol.* 82:33-64).

[0070] Preferably, collagen produced in accordance with the present invention will be purified using a combination of purification techniques, such as precipitation, solubilization and ion exchange chromatography followed by fibril formation.

[0071] Recovered or purified collagen may be treated to produce gelatin. Recombinant collagen produced in accordance with the invention may be converted to gelatin by any technique known in the art, such as thermal denaturation, acid treatment, alkali treatment, or any combination thereof. Alternately, gelatin may be produced essentially directly by expression of collagen monomers in recombinant host cells lacking prolyl4-hydroxylase activity at temperatures sufficiently high so as to denature the monomers as they are produced (e.g., about 26-37° C, more preferably about 30° C).

[0072] After purification, collagen of the invention may be modified to modulate its properties. Crosslinking can improve the thermal stability of trimeric fibrillar collagen, especially if the collagen is nonhydroxylated collagen. Methods for crosslinking collagen are known in the art, and are disclosed, for example, in McPherson et al. (1986, *J. Biomed Mat. Res.* 20:79-92). In general, the collagen is resuspended in a buffered solution such as phosphate buffered saline at about 3 mg/ml, and mixed with a relatively low concentration of glutaraldehyde, preferably about 0.0025-1% (v/v), more preferably 0.004-0.0075%. Preferably, the glutaraldehyde is of high purity and contains relatively low amounts of glutaraldehyde polymer. Glutaraldehyde polymer absorbs 235 nm light strongly, and so a ratio of absorbances at 280 and 235 nm can be used to assess the purity of glutaraldehyde preparations. Preferably, the glutaraldehyde has a 280 nm:235 nm ratio of about 1.8 to 2.0.

[0073] The collagen/glutaraldehyde mixture is incubated to allow crosslinking to occur. Preferably, the mixture is incubated at reduced temperature (i.e., less than about 20° C), preferably from about 4° C to about 18° C, with preferred temperatures being about 15° C to about 17° C. The crosslinks stabilize the collagen fibers against thermal denaturation of the triple helix, thereby maintaining the proteolytic resistance and structural integrity of the trimeric collagen.

[0074] The patents, patent applications, and publications cited throughout the disclosure are incorporated herein by

reference in their entirety.

EXAMPLES

Example 1: Recombinant Production of Type I Telopeptide Collagen

[0075] Recombinant type I telopeptide collagen ($\alpha 1$ homotrimer and $\alpha 1/\alpha 2$ heterotrimer) was produced in *S. cerevisiae* host cells using expression constructs coding for human $\alpha 1(I)$ and $\alpha 2(I)$ collagen monomers. A number of different shuttle vectors were created, most based on Gp5432 (see Fig. 2 for a map of Gp5432) which contains DNA encoding the procollagen $\alpha 1(I)$ and $\alpha 2(I)$ monomers operably linked to the bidirectional GAL1-10 promoter (the sequences of prepro $\alpha 1(I)$ and prepro $\alpha 2(I)$ are shown in Figs. 3 and 4, respectively). The PGK terminator (PGKt) is supplied at the 3' end of the $\alpha 2(I)$ sequence, while a terminator in the 2 μ DNA (from the FLP gene) acts to terminate transcription of the $\alpha 1(I)$ gene. Gp5432 also contains a yeast selectable marker (TRP1), an operable 1.6 kb fragment of the 2 μ yeast origin, a bacterial ori, and a bacterial selectable marker (*bla*). Additionally, a construct was made based on Gp5102, which is very similar to Gp5432 but does not contain the $\alpha 2(I)$ sequence or the PGKt (see Fig. 7 for a map of Gp5102). Constructs were created from Gp5432 which: (a) replaced the collagen secretion signal sequence (the "pre" domain) with a prepro domain from human serum albumin (HSA) which additionally contains a KEX2 protease processing site (MKWVTFISLLFLFSSAYSRGVFR in single letter amino acid code (the KEX2 protease cleaves at the carboxy-end of RR), designated pGET462); (b) encoded pC $\alpha 1(I)$ and pC $\alpha 2(I)$ linked to the preproHSA/KEX2 protease recognition sequence (designated pDO243880); and (c) and constructs with the $\alpha 1(I)$ and $\alpha 2(I)$ mature domain (*i.e.*, the signal sequence and the N and C propeptides were deleted from the preproCOL1A1 and preproCOL1A2) linked to the preproHSA/KEX2 protease recognition sequence or their native signal sequences (designated pDO248053 and pDO248098, respectively). pDO248010 was created from Gp5102, and encodes the $\alpha 1(I)$ telopeptide sequence linked to the preproHSA/KEX2 protease recognition sequence.

[0076] The expression constructs were transformed into GY5361 by electroporation. This host strain also contained a chromosomally-integrated expression construct encoding for the two subunits of chicken prolyl-4-hydroxylase. The alpha subunit (Bassuk et al., 1989, *Proc. Natl. Acad. Sci. USA* 86:7382-7386) and beta subunit, also known as PDI (Kao et al., 1988, *Conn. Tiss. Res.* 18:157-174), were cloned into an expression construct under the control of the bidirectional GAL 1-10 promoter. The prolyl-4-hydroxylase construct also included the *URA3* selectable marker and sequences from the *TRP1* gene to allow integration by homologous recombination. Correct integrants were *trp1*.

[0077] After electroporation of GY5361 with 100 ng of plasmid DNA, transformants were selected on 2% agar plates containing 2% dextrose, 0.67% yeast nitrogen base lacking amino acids (YNB), 0.5% casamino acids by growing 3 days at 30 °C. Transformants were grown overnight at 30 °C in media containing 2% dextrose, 0.67% YNB, 0.5% casamino acids to an OD₆₀₀ of 3 (approximately 1×10^8 cells/ml). To induce collagen expression, the overnight cultures (in glucose-containing media) were dilute to OD₆₀₀ of approximately 0.05 in media containing 0.5% galactose, 0.5% dextrose, 0.67% YNB and 0.5% casamino acids, 1% sodium citrate, pH 6.5, 50 mM sodium ascorbate, 300 mM α -ketoglutarate, 100 mM ferric chloride (FeCl₃), 100 mM glycine, 100 mM proline. Inductions were allowed to proceed for 48-96 hours at 30 °C.

[0078] Cells were harvested by centrifugation, resuspended in 0.1 M Tris HCl, pH 7.4, 0.4 M NaCl, 10 mM EDTA and lysed by vortexing in a centrifuge tube with glass beads. The beads and cellular debris were removed by centrifugation. Production of type I collagen was measured by immunoassay and protease sensitivity.

[0079] Collagen yield was determined using a luminometric immunoassay. The assay utilizes a goat anti-type I collagen antibody commercially available from Biodesign International (Kennebunk, ME) derivatized with either biotin or ruthenium chelate. Samples were diluted from 1:40 to 1:60 in "Matrix buffer" (100 mM PIPES, pH 6.8, and 1% w/v bovine serum albumin) and 25 μ l samples were dispensed into tubes. 50 μ l of an antibody working solution containing 1 μ g/ml of ruthenium chelate conjugated antibody and 1.5 μ g/ml biotin conjugated antibody in diluent (Matrix buffer plus 1.5% Tween-20) was added to each tube and the tubes were incubated for two hours at room temperature (approximately 20 °C). After the incubation, 25 μ l of a 1 mg/ml solution of streptavidin-conjugated magnetic beads (in diluent) were added to each tube. The tubes were shaken or vortexed for 30 seconds. 200 μ l of assay buffer (ORIGEN assay buffer, Igen, Inc., catalog number 402-050-01) was added to each tube and the tubes were mixed then placed in a ORIGIN analyzer (Igen, Inc., model #1100-1000). Total protein was determined using the BCA assay (Pierce) according the manufacturer's instructions. Results are shown below in Table 1.

TABLE 1

Strain	Proteins encoded	Expression levels (μ g collagen/mg protein)
CYT 30	preproCOL $\alpha 1(I)$ /preproCOL $\alpha 2(I)$	0.68 \pm 0.046

TABLE 1 (continued)

Strain	Proteins encoded	Expression levels (μg collagen/mg protein)
CYT 31	preproHSA α 1(I)/preproHSA α 2(I)	0.43 ± 0.015
CYT 32	preproHSA α 1(I)/preproHSA α 2(I)	1.21 ± 0.19
CYT 33	preproHSA α 1(I)/preproHSA α 2(I)	1.50 ± 0.038
CYT 44	preCOL α 1(I)/preCOL α 2(I)	0.13 ± 0.022

[0080] The constructs expression α 1 and α 2 linked to their native signal sequences gave reduced expression, which is believed to be due to an alteration of the amino acid context at the signal peptidase cleavage site, which impairs signal peptide processing.

[0081] The collagens were also tested by proteolytic assays for thermal stability. Resistance to pepsin or trypsin/chymotrypsin was measured by the method of Bruckner et al. (1981, *Anal. Biochem.* 110:360-368). Basically, samples were incubated with protease at a series of temperatures (4, 20, 25, 30 and 35 °C for pepsin and 20, 25, 30 and 35 °C for trypsin/chymotrypsin). Type I collagen from human skin fibroblasts was incubated with pepsin or trypsin/chymotrypsin as a standard. Results were assayed by western blotting (Towbin et al., 1979, *Proc. Natl. Acad. Sci. USA* 76: 4350-4354) using a rabbit anti-type I collagen antibody from Rockland, Inc. (Gilbertsville, PA), detected with a peroxidase-labeled goat anti-rabbit IgG (H + L) and visualized with a chemiluminescent reaction (ECL Western Blotting Kit, Amersham, Inc.). Assay results for α 1(I)/ α 2(I) heterotrimer are shown in Fig. 5. α 1(I) homotrimer had equivalent thermal stability as measured by this assay (data not shown).

[0082] In this assay, the triple helical portions of the collagen trimer are resistant to protease digestion. As the temperature is increased to the melting point of the triple helical region, the triple helical portions of the molecule become susceptible to proteolytic digestion. Monomeric collagen chains and improperly folded collagen monomers are highly susceptible to protease at low temperatures. These results show that the collagen produced by expression of DNA encoding α 1(I) and α 2(I) collagen lacking the N and C propeptides is approximately equivalent to human skin fibroblast type I procollagen with regards to thermal stability and protease resistance.

[0083] The correct folding and register of the three monomers in the yeast-produced triple helical collagen was assayed by digestion with mammalian collagenase. Human skin fibroblast collagenase cleaves each of the three chains of collagen at a single point. Collagenase is highly sensitive to local structure and sequence at the cleavage site. If the molecule is improperly folded or the chains are folded out of register, collagenase will not cleave (Wu et al., 1990, *Proc. Natl. Acad. Sci. USA* 78:5888-5892). Samples were digested with purified human fibroblast collagenase in 0.05 M Tris-HCl, pH 7.5, 0.15 M NaCl, 0.01 M CaCl_2 for 16 hours at 25 °C. Prior to use in the assay, procollagenase was activated by treatment with 10 $\mu\text{g}/\text{ml}$ trypsin at 25 °C for 30 minutes. The activation reaction was stopped by the addition of soybean trypsin inhibitor to a final concentration of 50 $\mu\text{g}/\text{ml}$. Results were displayed by western blotting using the same system as used for assaying protease resistance and are shown in Fig. 6. The data indicate that collagen produced by expression of DNA encoding α 1(I) and α 2(I) collagen lacking the N and C propeptides is correctly folded and the monomer chains are assembled in correct register.

Example 2: Construction of Host Cell Strains

[0084] Strains of *S. cerevisiae* which contain the subunits of prolyl-4-hydroxylase integrated into the *TRP1* gene, a mutation in the *GAL1* gene, a mutation in the *LEU2* gene, and a mutation in the *SUC2* gene were created for use in recombinant collagen production.

[0085] Strain YPH499a (*MAT α ura3-52 lys2-801 ade2-101a trp1- Δ 63 his3- Δ 200 leu2 Δ GAL*) was crossed to strain X2180-1B (*MAT α SUC mal mel gal2 CUP1*) to produce diploid strain GY5020. GY5020 was induced to sporulate and colonies from random spores were screened for genotypes *MAT α ura3-52 GAL*, *MAT α leu2 Δ GAL* and *MAT α trp1- Δ 63 ura3-52 GAL SUC*. One colony of each genotype was selected and designated GY5203, SC1214, and GY 5198, respectively.

[0086] SC1214 was crossed with YM147 (*MAT α gal1- Δ 102 ura3-52 trp1-289a*, (obtained from Mark Johnston of Washington University) to produce diploid strain GY5193, which was induced to sporulate. Colonies from randomly selected spores were screened for genotypes *MAT α leu2 Δ GAL* and *MAT α leu2 Δ ura3-52 gal1- Δ 102* and designated GY5209 and GY5208, respectively.

[0087] GY5209 was crossed to GY5151 (strain 11a obtained from David Botstein of Stanford University), *MAT α trp1 ura3 lys2 suc2 Δ gal*) to produce diploid strain GY5291. GY5291 was sporulated and tetrads were dissected to isolate a colony with the genotype *MAT α Leu2 Δ suc2 Δ GAL*, which was designated GY5357.

[0088] Strain GY5203 (*MAT α ura3-52 GAL+*) was transformed with a linear DNA containing the genes encoding the two subunits of prolyl-4-hydroxylase (cPDI and cP4-H) under the control of pGAL1-10, the *URA3* gene and sequence

targeting the DNA into the *TRP1* locus by homologous recombination. Integrants were selected for the presence of the *URA3* allele by growth on selective media, and further selected for high levels of expression of the prolyl-4-hydroxylase subunits. A *URA3* colony which produced high levels of the prolyl-4-hydroxylase subunits was streaked out, and a single colony was selected and designated GY 5344 (*MATa ura3-52 GAL trp1::[cPDI cP4-H URA3]*).

[0089] GY5344 was crossed to GY5357, and the resulting diploid was sporulated and analyzed by tetrad dissection. Trp⁺ colonies from tetrads containing 4 Ura⁺ segregants were selected and transformed with Gp5432. Transformants were analyzed for collagen expression. The colony which had the highest level of collagen expression after transformation with Gp5432, GY5381, was found to be *MATa ura3-52 suc2Δ trp1::[cPDI, cP4-H URA3]*.

[0090] GY5381 was crossed to GY5208 to yield diploid strain GY5349. GY 5349 was sporulated and the resulting tetrads were dissected. Colonies arising from individual spores were transformed with Gp5432 and analyzed for collagen expression. The colony which gave the best collagen expression after transformation with Gp5432 was designated GYT3681 (*MATa ura3-52 gal1Δ 102 trp1::[cPDI, cP4-H URA3]*). GY5362 (*MATa ura3-52 gal1Δ 102 trp1::[cPDI, cP4-H URA3] suc2Δ leu2Δ 1*) and GY5364 (*MATa ura3-52 gal1Δ 102 trp1::[cPDI, cP4-H URA3] suc2Δ leu2Δ 1*) were also isolated from the tetrad dissection of GY5349.

[0091] GY5198 was transformed with a linear DNA derived from Gp5551 (FIG. 12), which contains the *gal4*-mini marker, the *URA3* selectable marker, and sequences targeting homologous recombination into the *HIS3* locus. Transformants were selected for the presence of *URA3*, and screened for collagen production by transformation with Gp5511 (which carries genes encoding α1 and α2 telopeptide collagen monomers as well as the two subunits of prolyl-4-hydroxylase, and is diagrammed in FIG. 11). Strain GY5355 was selected on the basis of high collagen expression after transformation with Gp5511.

[0092] GY5362 was transformed with Gp5432 to yield GYT3683 (*MATa ura3-52 gal1Δ 102 trp1::[cPDI, cP4-H URA3] suc2Δ leu2Δ 1 + Gp5432*), which was crossed to GY5355 to generate diploid strain GYT3690. GYT3690 was induced to sporulate and analyzed by tetrad dissection. Several *MATa TRP⁺ his⁺ gal⁻* colonies were analyzed with respect to procollagen expression, and the colony with the highest expression was designated GYT3728 (*MATa ura3-52 gal1Δ 102 trp1::[cPDI cP4-H URA3] his3::[gal4-mini URA3] + Gp5432*).

[0093] GYT3728 was crossed to GY5364 (*MATa ura3-52 gal1Δ 102 trp1::[cPDI, cP4-H URA3] suc2Δ leu2Δ 1*) to yield diploid GYT3737. Tetrad dissection was performed, and colonies arising from individual spores were analyzed for procollagen production and thermal stability of the procollagen (a measure of prolyl-4-hydroxylase activity). Three strains, GYT3721 (*MATa ura3-52 gal1Δ 102 trp1::[cPDI cP4-H URA3] + Gp5432*), GYT3732 (*MATa ura3-52 gal1Δ 102 trp1::[cPDI cP4-H URA3] suc2Δ leu2Δ 1 + Gp5432*), and GYT3733 (*MATa ura3-52 gal1Δ 102 trp1::[cPDI cP4-H URA3] suc2Δ leu2Δ 1 + Gp5432*) were selected for high procollagen expression and high thermal stability. Thermal stability was highest in collagen produced by GYT3731.

[0094] GYT3731, GYT3732 and GYT3733 were "cured" of Gp5432 by culture in non-selective media (e.g., media containing tryptophan) followed by screening for TRP⁺ strains. One strain which retained the genotype of the parent strain (with the exception of the presence of Gp5432) was isolated for each parent, and designated GY5382 (sometimes referred to as G3), GY5379 (sometimes referred to as G95) and GY5385 (sometimes referred to as G98), respectively.

Example 3: Recombinant Collagen Production in Yeast with Defined Media

[0095] Defined media utilizing no animal-derived components were tested for use in collagen production. Strain GYT3731 (strain GY5382, described above, transformed with plasmid Gp5432) was used for these experiments. YNB (Difco) was the base media for these experiments.

[0096] Overnight cultures of GYT3731 were grown in YNB with 2% glucose (w/v) and 0.5% casamino acids (w/v). The overnight cultures were used to inoculate 5 ml test cultures to a starting optical density (OD) of 0.1. Growth and procollagen production were assayed after a 60-65 hour incubation. The cells were collected by centrifugation, resuspended in PBS, mixed with an equal volume of acid-washed glass beads, and frozen at -70° C. The cells were thawed and lysed by vortexing for 6 minutes, then assayed by immunoassay as described in Example 1.

[0097] YNB, 2% glucose, 0.5% galactose was tested with and without 0.5% CAA or an amino acid cocktail (AA, 20 mg/L arginine HCl, 100 mg/L sodium glutamate, 20 mg/L histidine, 30 mg/L lysine HCl, 20 mg/L methionine, 50 mg/L phenylalanine, 375 mg/L serine, 20 mg/L tryptophan, 30 mg/L tyrosine, 150 mg/L valine). The cells grown in media with CAA grew to a higher final density and showed greatly enhanced procollagen production compared to YNB alone or YNB + AA. Procollagen production data is shown in Table 2.

TABLE 2

Medium	Procollagen Production (μg/mg total protein)
YNB	0.04

TABLE 2 (continued)

Medium	Procollagen Production ($\mu\text{g}/\text{mg}$ total protein)
YNB + 0.5% CAA	2.48
YNB + AA	0.1

CAA supplementation supports a substantial improvement in procollagen production as compared to YNB alone or with the AA amino acid mixture

[0098] The optimal concentration of CAA supplementation was tested by using a range of concentrations of CAA. Results are shown in Fig. 9. 0.5% CAA supplementation supports the highest levels of procollagen production.

[0099] CAA was compared to the media supplements Bacto Tryptone® (BT), Bacto Peptone® (BP) and yeast extract (YE), utilizing the same protocol as above. Results are shown in Table 3.

TABLE 3

Medium	Procollagen Production ($\mu\text{g}/\text{mg}$ total protein)
YNB + 0.25% CAA	2.34
YNB + 0.5% CAA	4.24
YNB + 1% CAA	1.54
YNB + 0.25% BT	1.92
YNB + 0.5% BT	1.81
YNB + 1% BT	1.14
YNB + 0.25% BP	0.76
YNB + 0.5% BP	1.15
YNB + 1% BP	1.46
YNB + 0.25% YE	1.74
YNB + 0.5% YE	2.33
YNB + 1% YE	1.53
YNB	0.26

[0100] CAA is an animal-derived product. Such products are disadvantageous for production of materials for medical use, due to regulatory issues. Since CAA appears to be the most stimulatory for procollagen production, simpler amino acid mixtures, based on the concentrations that would be found in medium containing 0.5% CAA (which are significantly higher levels than previously used for the AA cocktail used in the experiments described in Table 2) were made and tested to identify the stimulatory component(s). YNB was supplemented with RQK (110 mg/L arginine HCl, 765 mg/L sodium glutamate and 286 mg/L lysine HCl), Q (1534 mg/L sodium glutamate), or α K (3063 mg/L disodium α -ketoglutarate). Results are shown in Table 4.

TABLE 4

Medium	Procollagen Production ($\mu\text{g}/\text{mg}$ total protein)
YNB + 0.5% CAA	3.64 (n=3)
YNB + RQK	3.71
YNB + Q	3.44
YNB + α K	3.32

All three amino acid supplements supported procollagen expression levels approximately equal to that of YNB + 0.5 % CAA.

[0101] The effect of pH on the effectiveness of the α K supplement was tested. YNB was supplemented with α -ketoglutarate to 1534 mg/L, and tested without added pH buffer or with PO_4 (50 mM sodium phosphate, pH 7.0), Succ (50 mM sodium succinate, pH 6.5) or Cit (1% sodium citrate (47.6 mM), pH 6.0) buffer. Results are shown in Table 5.

TABLE 5

Medium	Procollagen Production ($\mu\text{g}/\text{mg}$ total protein)	Final pH
YNB + α K	1.11	2.77

TABLE 5 (continued)

Medium	Procollagen Production ($\mu\text{g}/\text{mg}$ total protein)	Final pH
YNB + $\alpha\text{k}/\text{PO}_4$	1.75	5.36
YNB + $\alpha\text{k}/\text{Succ}$	2.23	5.30
YNB + $\alpha\text{K}/\text{Cit}$	3.12	5.41

Decreased pH appears to increase procollagen production in defined media supplemented with α -ketoglutarate.

Example 4: pN and pC Collagen Production in Yeast

[0102] Constructs were created to express four different triple helical type I collagens: procollagen, pN collagen, pC collagen, and collagen lacking both the N and C propeptides (telopeptide collagen). The expression constructs were based on plasmid Gp5432 and included sequences encoding both the $\alpha 1(\text{I})$ and $\alpha 2(\text{I})$ monomers. Each construct contained a heterologous prepro sequence (from the HSA gene, as described in Example 1).

[0103] Each construct was transformed into strain GY5382, described above in Example 2. A colony from each transformation was selected, and the strains were designated CYT 89 (procollagen), CYT 87 (pN collagen), CYT 90 (pC collagen) and CYT 59 (telopeptide collagen).

[0104] Each strain was grown in YNB buffered with 1% sodium citrate, pH 6.5, and supplemented with 10 g/L glucose, 5 g/L galactose, 0.5% casamino acids. Each culture was grown at 30° C and harvested at 100 hours. Collagen production was assayed as described above in Example 1. Assay results are shown in Table 6.

TABLE 6

Medium	Collagen Production ($\mu\text{g}/\text{mg}$ total protein)
CYT 89 (procollagen)	1.64
CYT 87 (pN collagen)	6.45
CYT 90 (pC collagen)	9.7
CYT 59 (telopeptide collagen)	29.8

Example 5: Production of hydroxylated telocollagen in yeast cells

[0105] Strain CYT59 (strain GY5382 transformed with pDO248053) was cultured in a yeast fermentation apparatus for ~120 hours. The recombinant yeast were collected by centrifugation from six liters of fermentation broth and chilled to 8° C (all subsequent steps were performed at 8° C unless otherwise noted). The pelleted cells were resuspended in four liters of 0.1 M Tris-HCl, 0.4 M NaCl, pH 7.4, and lysed by passing the cell suspension through a Dyno-Mill KDL Special containing 500 grams of acid-washed glass beads at a flow rate of 75 ml/minute. The resulting lysate was centrifuged at 16,000 x g for 1 hour to remove cellular debris. The clarified lysate was delipidated by the addition of 80 grams of CELITE® 512 followed by stirring for one hour. The mixture was then filtered in two passes through Whatman GF/F glass fiber filter (0.7 μm) with Whatman GF/D as a prefilter to remove the Celite and any other insoluble material.

[0106] Collagen was precipitated from the clarified, delipidated solution by the addition of NaCl crystals to the solution to make it 3.9 M in NaCl, followed by gentle mixing overnight. The precipitated collagen was collected by centrifugation, then washed by resuspension in 0.1 M Tris-HCl, pH 7.4, 3.5 M NaCl followed by centrifugation. The pelleted collagen was resuspended in 0.1 M Tris-HCl, pH 7.4 with stirring overnight. The resuspended collagen solution was clarified by centrifugation, then dialyzed against 100 volumes of 50 mM sodium acetate, pH 4.5. A precipitate formed during dialysis which was removed by centrifugation at 26,000 x g for one hour. The supernatant was passed over a 250 ml SP-SEPHAROSE® column which had been equilibrated in 50 mM sodium acetate, pH 4.5. The column was washed with 50 mM sodium acetate, then eluted in a single step with 50 mM sodium acetate, pH 4.5, 0.45 M NaCl. The eluted material was concentrated by ultrafiltration using an Amicon stirred cell under positive pressure and a YM-10 membrane. The concentrated collagen was then precipitated by making the solution 1.2 M in NaCl, 10 mM HCl. The precipitate was collected by centrifugation at 26,000 x g for one hour and resuspended in 10 mM HCl at a concentration of 3 mg/ml. The acidified collagen solution was dialyzed against 100 volumes of 20 mM sodium phosphate, pH 7.2, at 15° C, overnight.

[0107] A suspension of collagen fibers was diluted 20 mM sodium phosphate, pH 7.2, to a final collagen concentration of 0.25-0.5 mg/ml, and transferred to thin bar, high definition square 400 mesh copper grids (Polysciences, Inc.), washed, and dried in a dessicator overnight. The grids were negatively stained with 1% phosphotungstic acid, pH 7.

The grids were examined and photographed in a Joel 1200EX transmission electron microscope operating at 80 kV. A photomicrograph of recombinant collagen fibers (30,000 x magnification) is shown in Fig. 10. The fibrils display the characteristic banding pattern of collagen fibrils.

[0106] The present invention has been detailed both by direct description and by example. Equivalents and modifications of the present invention will be apparent to those skilled in the art, and are encompassed within the scope of the invention.

Claims

1. A method for the production of fibrillar collagen comprising:
 - culturing a recombinant host cell comprising a DNA encoding a fibrillar collagen monomer lacking a C propeptide SSAD under conditions appropriate for expression of said DNA; and
 - producing fibrillar collagen.
2. The method of claim 1 wherein said DNA encodes a fibrillar collagen monomer lacking at least 50%, 75%, 90% or all of the C propeptide.
3. The method of claim 1 wherein said DNA encodes a fibrillar collagen lacking a C propeptide SSAD and lacking a N propeptide.
4. The method of any one of claims 1, 2 or 3 wherein said DNA encodes a fibrillar collagen selected from the group consisting of collagen $\alpha 1(I)$, collagen $\alpha 2(I)$, collagen $\alpha 1(III)$, collagen $\alpha 1(V)$, collagen $\alpha 2(V)$, collagen $\alpha 3(V)$, collagen $\alpha 1(XI)$, collagen $\alpha 2(XI)$, and collagen $\alpha 3(XI)$.
5. The method of any one of the preceding claims wherein said DNA is operably linked to a second DNA sequence encoding a heterologous prepro sequence.
6. The method of claim 5 wherein said heterologous prepro sequence is a human serum albumin prepro sequence.
7. The method of any one of the preceding claims wherein said host cell is selected from a yeast cell, an insect cell, a bacterial cell or a mammalian cell.
8. The method of claim 7 wherein said host cell is selected from a *Saccharomyces cerevisiae* cell, a *Pichia pastoris* cell, an *Escherichia coli* cell or a HT-1080 cell.
9. The method of any one of the preceding claims wherein said host cell is cultured in defined media.
10. The method of claim 9 wherein said defined media comprises at least one amino acid selected from the group consisting of arginine, glutamic acid, lysine and α -ketoglutarate, or said defined media comprises arginine, glutamic acid and lysine, but no other amino acids.
11. The method of claim 9 or claim 10 wherein said defined media comprises a pH buffer which buffers the defined media to about pH 5.5 to about pH 7.0.
12. The method of claim 11 wherein said defined media comprises a pH buffer which buffers the defined media to about pH 6.0.
13. The method of any one of the preceding claims wherein said host cell comprises DNA encoding active prolyl-4-hydroxylase or said host cell does not comprise DNA encoding active prolyl-4-hydroxylase.
14. A method for the production of fibrillar procollagen, comprising:
 - culturing a recombinant yeast host cell comprising a DNA encoding a fibrillar collagen monomer lacking a N propeptide under conditions appropriate for expression of said DNA; and
 - producing fibrillar collagen.

15. The method of claim 14 wherein said DNA comprises sequence encoding a fibrillar collagen monomer lacking a N-propeptide linked to a non-collagen signal sequence.

5 16. A mature fibrillar telopeptide collagen, wherein said collagen lacks native glycosylation and has genuine amino and carboxy terminal ends.

17. A mature fibrillar telopeptide collagen produced by expression of a DNA construct encoding a fibrillar collagen monomer lacking a C propeptide SSAD and a N propeptide.

10 18. A recombinant host cell comprising:
an expression construct comprising DNA encoding a fibrillar collagen monomer lacking a C propeptide SSAD.

19. A mature fibrillar telopeptide collagen lacking native glycosylation and having genuine amino and carboxy terminal
15 ands produced by a method comprising:

culturing a recombinant host cell comprising a DNA encoding a fibrillar collagen monomer lacking a C propeptide and a N propeptide under conditions appropriate for expression of said DNA; and
producing fibrillar collagen.

20 20. A method of producing telopeptide collagen fibrils, comprising:

culturing a recombinant host cell comprising a DNA encoding a fibrillar collagen monomer lacking a C propeptide and a N propeptide under conditions appropriate for expression of said DNA, thereby producing fibrillar
collagen;

25 recovering said fibrillar collagen; and
forming fibrils from said fibrillar collagen.

21. The method of claim 20, wherein said method further comprises purifying said recovered fibrillar collagen.

30 22. A method of producing gelatin, comprising culturing a recombinant host cell comprising a DNA encoding a collagen monomer lacking a N or C propeptide under conditions appropriate for expression of said DNA; and
producing gelatin.

FIG. 1

<u>Monomer</u>	1	23
$\alpha 1(I)$	GGQGSDPADVAIQLTFLRLMSTE	
$\alpha 2(I)$	NVEGVTSKEMATQLAFMRLLANY	
$\alpha 1(II)$	GDDNLAPNTANVQMTFLRLLSTE	
$\alpha 1(III)$	FNPELPEDVLDVQLAFLRLLSSR	
$\alpha 1(V)$	VDAEFNPVGV VQMTGLRLLSAS	
$\alpha 2(V)$	GDHQSPNTAI TQMTFLRLLSKE	
$\alpha 1(XI)$	LDVEGNSINM VQMTFLKLLTAS	
$\alpha 2(XI)$	VDSEGSPVGV VQLTFLRLLSVS	

FIG. 2




FIG. 3A

1 50
MESEVDLRLLL LLLAATAALLT HGQEEGQVEG QDEDIPPITC VQNGRLRYHDR
 51 100
 DVWKPEPCRI CVCDNGKVLC DDVICDETKN CPGAEPVEGE CCPVCPDGSE
 101 150
 SPTDQETTGV EGD TGPRGPR GPAGPPGRDG IPGQPGLPGP PGPPGPPGPP
 151 * 200
 GLGGNFAPQL SYGYDEKSTG GISVPGPMGP SGPRGLPGPP GAPGPQGFGQ
 201 250
 PPGEPEPGA SGPMGPRGPP GPPGKNGDDG EAGKPGRPGE RGPPGPQGAR
 251 300
 GLPGTAGLPG MKGHRGFSGL DGA KGDAGPA GPKGEPSPG ENGAPQMGP
 301 350
 RGLPGERCRP GAPGPAGARG NDGATGAAGP PGPTGPAGPP GFPGAVGAKG
 351 400
 EAGPQGPRGS EGPQGVREGE GPPGPAGAAG PAGNPGADGQ PGAKGANGAP
 401 450
 GIAGAPGFPG ARGPSGPQGP GGPPGPKGNS GEPGAPGSKG DTGAKGEPPG
 451 500
 VGVQGPPGPA GEEGKRGARG EPGPTGLPGP PGERGGPGSR GFPGADGVAG
 501 550
 PKGPAGERGS PGPA GPKGSP GEAGRPGEAG LPGAKGLTGS PGSPGPDGKT
 551 600
 GPPGPAGQDG RPPGPPPPGA RGQAGVMGFP GPKGAAGEPG KAGERGVPGP
 601 650
 PGAVGPAGKD GEAGAQQPPG PAGPAGERGE QGPAGSPGFQ GLPGPAGPPG
 651 700
 EAGKPGEQGV PGDLGAPGPS GARGERGFPG ERGVQGPPGP AGPRGANGAP
 701 750
 GNDGAKGDAG APGAPGSQGA PGLQGMPGER GAAGLPGPKG DRGDAGPKGA
 751 800

FIG. 3B

DGSPGKDGVR GLTGPIGPPG PAGAPGDKGE SGPSGPAGPT GARGAPGDRG
 801 850
 EPGPPGPAGF AGPPGADGQP GAKGEPGDAG AKGDAGPPGP AGPAGPPGPI
 851 900
 GNVGAPGAKG ARGSAGPPGA TGPPGAAGRV GPPGPSGNAG PPGPPGPAGK
 901 950
 EGGKGPRGET GPAGRPGEVG PPGPPGPAGE KGSPGADGPA GAPGTPGPQG
 951 1000
 IAGQRGVVGL PGQRGERGFP GLPGPSGEPG KQGPPSGASGE RGPPGPMGPP
 1001 1050
 GLAGPPGESG REGAPGAEGS PGRDGSPGAK GDRGETGPAG PPGAPGAPVA
 1051 1100
 PGPVGPAGKS GDRGETGPAG PAGVGPVGA RGPAGPQGPR GDKGETGEQG
 1101 1150
 DRGIKGHRGF SGLQGPPGPP GSPGEGQPSG ASGPAGPRGP PGSAGAPGKD
 1151 1200
 GLNGLPGPIG PPGPRGRTGD AGPVGPPGPP GPPGPPGPPS AGFDFSFLPQ
 1201 # 1250
 PPQEKAHGEG RYYRADDANV VRDRDLEVDT TLKSLSQQIE NIRSPEGSRK
 1251 1300
 NPARTCRDLK MCHSDWKSSE YWIDPNQGCN LDAIKVFCNM ETGETCVYPT
 1301 1350
 QPSVAQKNWY ISKNPKDKRH VWFGESMTDG FQFEYGGQGS DPADVAIQLT
 1351 1400
 FLRLMSTEAS QNITYHCKNS VAYMDQQTGN LKKALLLKGS NEIEIRAEGN
 1401 1450
 SRFTYSVTVD GCTSHTGAWG KTVIEYKTTK TSRLPIIDVA PLDVGAPDQE
 1460 1461
 FGFDVGPVCF L

FIG. 4A

1 50
 MLSEVDTRTL LLLAVTLCLA TCQSLQEETV RKGPAGDRGP RGERGPPGPP
 51 * 100
 GRDGEDGPTG PPGPPGPPGP PGLGGNFAAQ YDGKGVGLGP GPMGLMGPRG
 101 150
 PPGAAGAPGP QGFQGPAGEP GEPGQTGPAG ARGPAAGPPGK AGEDGHPGKP
 151 200
 GRPGERGVVG PQGARGFPPT PGLPGFKGIR GHNGLDGLKG QPGAPGVKGE
 201 250
 PGAPGENGTP GQTGARGLPG ERGRVGAPGP AGARGSDGSV GPVGPAGPIG
 251 300
 SAGPPGFPGA PGPKGEIGAV GNAGPAGPAG PRGEVGLPGL SGPVGPNGP
 301 350
 GANGLTGAKG AAGLPGVAGA PGLPGPRGIP GPVGAAGATG ARGLVGEPGP
 351 400
 AGSKGESGNK GEPGSAGPQG PPGPSGEEGK RGPNGEAGSA GPPGPPGLRG
 401 450
 SPGSRGLPGA DGRAGVMGPP GSRGASGPAG VRGPNGDAGR PGEPLMGPR
 451 500
 GLPGSPGNIG PAGKEGPVGL PGIDGRPGPI GPAGARGEPE NIGFPGPKGP
 501 550
 TGDPGKNGDK GHAGLAGARG APGPDGNNGA QGPPGPQGVQ GGKGEQGPAG
 551 600
 PPGFQGLPGP SGPAGEVGKP GERGLHGEFG LPGPAGPRGE RGPPGESGAA
 601 650
 GPTGPIGSRG PSGPPGPDGN KGEPPGVVAV GTAGPSGPSG LPGERGAAGI
 651 700
 PGGKGEKGEF GLRGEIGNPG RDGARGAHGA VGAPGPAGAT GDRGEAGAAG
 701 750
 PAGPAGPRGS PGERGEVGPA GPNGFAGPAG AAGQPGAKGE RGAKGPKGEN
 751 800

FIG. 4B

GVVGPTGPVG AAGPAGPNGP PGPAGSRGDG GPPGMTGFPG AAGRTGPPGP
 801 850
 SGISGPPGPP GPAGKEGLRG PRGDQGPVGR TGEVGAVGPP GFAGEKGPSG
 851 900
 EAGTAGPPGT PGPQGLLGAP GILGLPGSRG ERGLPGVAGA VGEFGPLGIA
 901 950
 GPPGARGPPG AVGSPGVNGA PGEAGRDGNP GNDGPPGRDG QPGHKGERGY
 951 1000
 PGNIGPVGAA GAPGPHGPVG PAGKHGNRGE TGPSGPVGPA GAVGPRGPSG
 1001 1050
 PQGIRGDKGE PGEKGPRGLP GLKGHNGLQG LPGIAGHHGD QGAPGSVGPA
 1051 1100
 GPRGPAGPSG PAGKDGRTHG PGTVGPAGIR GPQGHQGPAG PPGPPGPPGP
 1101 # 1150
 PGVSGGGYDF GYDGDIFYRAD QPRSAPSLRP KDYEVDATLK SLNNQIETLL
 1151 1200
 TPEGSRKNPA RTCRDLRLSH PEWSSGYWI DPNQGCTMDA IKVYCDFSTG
 1201 1250
 ETCIRAQPEN IPAKNWYRSS KDKKHVWLGE TINAGSQFEY NVEGVTSKEM
 1251 1300
 ATQLAFMRLL ANYASQNITY HCKNSIAYMD EETGNLKKAV ILQGSNDVEL
 1301 1350
 VAEGNSRFTY TVLVDGCSKK TNEWGKTIIE YKTNKPSRLP FLDIAPLDIG
 1351 1366
 GADHEFFVDI GPVCFK




FIG. 5

Digestion of HSF and CYT 29 derived collagen with mammalian collagenase




FIG. 6




FIG. 7




FIG. 8




FIG. 9



FIG. 10

from sequence file)




FIG. 11




FIG. 12

Docket No.: FG0219 US
 Applicants: Chang et al.
 U.S. Serial No. 09/710,239
 Filing Date: 10 November 2000
 Title: RECOMBINANT GELATINS